Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report

Yamaguchi,Takashi; Seki,Toshihito; Miyasaka,Chika; Inokuchi,Ryosuke; Kawamura,Rinako; Sakaguchi,Yuutaku; Murata,Miki; Matsuzaki,Koichi; Nakano,Yorika; Uemura,Yoshiko; Okazaki,Kazuichi

doi:10.3892/ol.2015.2934

April-2015 Volume 9 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2015 Volume 9 Issue 4

Full Size Image

Case Report

Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report

Authors:
- Takashi Yamaguchi
- Toshihito Seki
- Chika Miyasaka
- Ryosuke Inokuchi
- Rinako Kawamura
- Yuutaku Sakaguchi
- Miki Murata
- Koichi Matsuzaki
- Yorika Nakano
- Yoshiko Uemura
- Kazuichi Okazaki
View Affiliations / Copyright

Affiliations: Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka 570-8507, Japan, Department of Diagnostic Pathology, Kansai Medical University, Osaka 570-8507, Japan
Pages: 1633-1636
|
Published online on: February 5, 2015

https://doi.org/10.3892/ol.2015.2934
Expand metrics +

Abstract

Sorafenib is a multikinase inhibitor currently approved in Japan for the treatment of unresectable hepatocellular carcinoma. Interstitial pneumonia induced by sorafenib may have a fatal outcome, and therefore, has recently been the focus of many studies. The current report presents an autopsy case of diffuse alveolar damage (DAD) that occurred in a 59‑year‑old male, who had been treated with sorafenib. The patient had been given sorafenib for six months and had exhibited no respiratory symptoms during this time. However, 19 days after sorafenib treatment was resumed, acute interstitial pneumonia developed. In previously reported cases, the first symptoms of pulmonary toxicity appeared following a limited treatment duration with sorafenib; this was in contrast to the patient in the current study, who developed the first symptoms after eight months. We therefore conclude that physicians must be aware of interstitial pneumonia as a potential pulmonary toxicity associated with sorafenib treatment when treatment with sorafenib is resumed, even after prolonged use. In addition, to best of our knowledge, this is the first case of a postmortem examination reported in patient with interstitial pneumonia induced by sorafenib treatment.

View Figures

View References

1	Wilhelm SM, Carter C, Tang L, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
3	Ide S, Soda H, Hakariya T, et al: Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event. Lung Cancer. 67:248–250. 2010. View Article : Google Scholar
4	Myung HJ, Jeong SH, Kim JW, et al: Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver. 4:543–546. 2010. View Article : Google Scholar
5	Takeda H, Nishikawa H, Iguchi E, et al: Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clin J Gastroenterol. 5:407–412. 2012. View Article : Google Scholar : PubMed/NCBI
6	Bayer Healthcare Japan. Safety information for Nexabar™ 200mg tablets. June. 2012, (In Japanese). http://www.nexavar.jp/ja/home/usage-information/servey-record/hcc/. Accessed March 10, 2014
7	Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
8	Myers JL and Katzenstein AL: Beyond a consensus classification for idiopathic interstitial pneumonias: progress and controversies. Histopathology. 54:90–103. 2009. View Article : Google Scholar
9	Esteban A, Fernández-Segoviano P, Frutos-Vivar F, et al: Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med. 141:440–445. 2004. View Article : Google Scholar : PubMed/NCBI
10	Zambon M and Vincent JL: Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 133:1120–1127. 2008. View Article : Google Scholar : PubMed/NCBI
11	Barber NA and Ganti AK: Pulmonary toxicities from targeted therapies: a review. Target Oncol. 6:235–243. 2011. View Article : Google Scholar : PubMed/NCBI
12	Muller NL, White DA, Jiang H, et al: Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 91(Suppl 2): S24–S30. 2004. View Article : Google Scholar : PubMed/NCBI
13	Schwaiblmair M, Behr W, Haeckel T, et al: Drug induced interstitial lung disease. Open Respir Med J. 6:63–74. 2012. View Article : Google Scholar : PubMed/NCBI
14	Abadie Y, Bregeon F, Papazian L, et al: Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur Respir J. 25:139–146. 2005. View Article : Google Scholar : PubMed/NCBI
15	Vasakova M, Sterclova M, Kolesar L, et al: Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol. 69:268–274. 2009. View Article : Google Scholar : PubMed/NCBI
16	Roberts JR, Perkins GD, Fujisawa T, et al: Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med. 35:2164–2170. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles